HelpAcademyLoginJoin us as a Member

Furmonertinib

Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yetListed from FDA or ClinicalTrials.gov records; an editor has not checked it yet.

ArriVent BioPharma, Inc. AVBP · Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations; Metastatic Non-Small Cell Lung Cancer

Sign in to save Furmonertinib to a watchlist Sign in to set an alert for Furmonertinib

Key figures

  • Next catalyst

    None scheduled

    Only dates with a source are listed

  • Phase

    Phase 3

    Not recorded

  • Linked trials

    1

    From ClinicalTrials.gov

  • Latest FDA action

    None on record

    From Drugs@FDA

Recalls, shortages, patents and EU status at a glance

Key information

Sponsor
ArriVent BioPharma, Inc. AVBP Source: Company record for ArriVent BioPharma, Inc. (opens in a new tab)
Indications
Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations; Metastatic Non-Small Cell Lung Cancer Source: Conditions from ClinicalTrials.gov (opens in a new tab)
Designations
None recorded
Next catalyst
None scheduled

Development timeline

  1. Preclinical Completed
  2. Phase 1 Completed
  3. Phase 2 Completed
  4. Phase 3 Current stageFirst trial start 1 Jun 20231 linked trial
  5. Filed Not yet
  6. Approved Not yet

Overview

Mechanism
Not recorded
Route
Not recorded
Modality
Not recorded
Specialties
Not recorded

Overview text is written by HealthTrade editors.

Key dates

No catalysts yet. Editors add each date together with its source.

FDA designations

No FDA designations are on record for Furmonertinib. Editors add each one with its source.

Filed application

No filed application is on record for Furmonertinib. Approvals are listed under FDA actions.

FDA advisory committees

No FDA advisory committee meetings are on record for Furmonertinib.

Clinical trials

Trials linked to Furmonertinib
TrialTitlePhaseStatusEnrollmentPrimary completionResults posted
NCT05607550ClinicalTrials.gov record for NCT05607550 (opens in a new tab)Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Phase 3Active, not recruiting398 (actual)15 Aug 2025 (estimated) No

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.

Trial quality

About CT-VCA

Loading trial quality…

FDA actions

No FDA approvals on record for this drug.

FDA recalls load here.

FDA drug shortages load here.

Orange Book patents load here.

FAERS adverse event counts load here.

Papers and preprints load here.

Community discussion loads here.

EU status (EMA)

EMA's medicines data lists no human medicine with the same active substance as Furmonertinib.

Source: European Medicines Agency (EMA), medicines data download.

Related news

No recent headlines mention this drug.

Sources

Record updated .

Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.